Goetz CG - Search Results

1

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P; members of the MDS Rating Scales Review Committee. Skorvanek M, et al. Among authors: goetz cg. Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23. Mov Disord. 2018. PMID: 29168899 Review.

2

Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.

Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Goldman JG, et al. Among authors: goetz cg. Arch Neurol. 2004 Aug;61(8):1280-4. doi: 10.1001/archneur.61.8.1280. Arch Neurol. 2004. PMID: 15313848

3

Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects.

Kompoliti K, Goetz CG, Morrissey M, Leurgans S. Kompoliti K, et al. Among authors: goetz cg. Mov Disord. 2006 Feb;21(2):248-52. doi: 10.1002/mds.20680. Mov Disord. 2006. PMID: 16161137

4

Goetz CG, Wuu J, Curgian L, Leurgans S. Goetz CG, et al. Mov Disord. 2006 Feb;21(2):267-70. doi: 10.1002/mds.20701. Mov Disord. 2006. PMID: 16161144

5

Does seasonal variation affect hallucinations in PD? A longitudinal study.

Goetz CG, Li JM, Wuu J, Leurgans S. Goetz CG, et al. Mov Disord. 2006 Jun;21(6):863-5. doi: 10.1002/mds.20840. Mov Disord. 2006. PMID: 16538649

6

The malignant course of "benign hallucinations" in Parkinson disease.

Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. Goetz CG, et al. Arch Neurol. 2006 May;63(5):713-6. doi: 10.1001/archneur.63.5.713. Arch Neurol. 2006. PMID: 16682540

7

Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations.

Kroonenberg PM, Oort FJ, Stebbins GT, Leurgans SE, Cubo E, Goetz CG. Kroonenberg PM, et al. Among authors: goetz cg. BMC Med Res Methodol. 2006 Jun 13;6:26. doi: 10.1186/1471-2288-6-26. BMC Med Res Methodol. 2006. PMID: 16772027 Free PMC article. Clinical Trial.

8

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Friedman JH, et al. Among authors: goetz cg. Mov Disord. 2006 Dec;21(12):2078-81. doi: 10.1002/mds.21091. Mov Disord. 2006. PMID: 17013906

9

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.

Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Goetz CG, et al. Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226. Mov Disord. 2007. PMID: 17094088 Clinical Trial.

10

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Goetz CG, et al. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198. Mov Disord. 2007. PMID: 17115387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

564 results

Search Page

Filters